Equities

KPC Pharmaceuticals Inc

600422:SHH

KPC Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.64
  • Today's Change-0.16 / -0.70%
  • Shares traded7.41m
  • 1 Year change+0.62%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.

  • Revenue in CNY (TTM)7.65bn
  • Net income in CNY432.35m
  • Incorporated1995
  • Employees5.05k
  • Location
    KPC Pharmaceuticals IncNo. 166Keyi Road, High-tech Development ZoneKUNMING 650106ChinaCHN
  • Phone+86 87 168324311
  • Fax+86 87 168324267
  • Websitehttp://www.kpc.com.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Liaoning Cheng Da Co Ltd11.18bn17.48m15.83bn3.36k796.150.5428--1.420.0130.0137.3419.070.23584.416.493,330,121.00-0.53663.59-0.76445.2116.0314.15-2.289.890.7792--0.283415.93-25.97-10.97-80.95-21.267.04--
Changchun BCHT Biotechnology Co1.92bn543.19m15.95bn1.24k29.313.90--8.331.321.324.649.880.41160.84591.551,543,550.0011.679.9514.1412.8189.9086.6328.3624.032.03--0.015810.5570.3012.36175.9831.3721.04--
Jiang Zhong Pharmaceutical Co Ltd4.30bn734.24m16.52bn4.01k22.524.00--3.841.171.176.836.550.66984.3413.621,071,799.0012.3510.8218.8215.0864.0165.0218.4418.171.47--0.006182.8813.0020.1218.408.5411.4740.99
KPC Pharmaceuticals Inc7.65bn432.35m17.14bn5.05k39.333.16--2.240.57570.575710.207.150.80212.482.621,513,702.004.635.427.769.1343.1243.685.775.701.4653.930.168835.75-6.991.6416.055.79-21.3314.87
Anhui Huaheng Biotechnology Co Ltd2.04bn454.44m18.04bn1.69k39.779.43--8.852.882.8812.9212.150.61965.598.041,205,674.0013.7116.7421.5922.4138.4939.2122.1322.340.4552155.980.455225.2036.6335.7240.3242.8482.09--
Dizal Jiangsu Pharmaceutical Co Ltd172.61m-1.09bn18.07bn581.00--25.94--104.70-2.67-2.670.4221.680.10080.32156.78297,086.40-63.79-46.02-82.62-52.9996.4157.53-632.90-2,081.541.74--0.4557----18.29-50.50--21.35--
Shandong Buchang Pharmaceuticals Co Ltd12.37bn-22.28m18.21bn8.31k--1.57--1.47-0.0202-0.020211.1810.460.56781.009.581,488,478.00-0.90133.26-1.304.7264.0574.71-1.594.850.53482.340.2522121.01-11.41-0.6219120.85-29.93-16.56-36.72
Data as of May 17 2024. Currency figures normalised to KPC Pharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

20.04%Per cent of shares held by top holders
HolderShares% Held
Zhong Ou Asset Management Co., Ltdas of 30 Jun 202340.26m5.32%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 202338.72m5.12%
Fullgoal Fund Management Co., Ltd.as of 30 Sep 202326.57m3.51%
First Seafront Fund Management Co., Ltd.as of 30 Jun 202316.05m2.12%
China Investment Corp. (Investment Management)as of 30 Sep 202311.81m1.56%
China Southern Asset Management Co., Ltd.as of 30 Jun 20235.17m0.68%
Great Wall Fund Management Co., Ltd.as of 30 Jun 20234.24m0.56%
Hotland Innovation Asset Management Co. Ltd.as of 30 Jun 20233.31m0.44%
China Universal Asset Management Co., Ltd.as of 30 Jun 20232.78m0.37%
GF Fund Management Co., Ltd.as of 30 Jun 20232.77m0.37%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.